---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-030777"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:46:56.388597+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics to merge with Peak Bio; Akari to issue ~50% of post-merger ADSs

## Summary
- Akari acquires Peak Bio via merger; Peak Bio survives as wholly-owned subsidiary.
- Consideration: Akari ADSs representing ~50% of outstanding Akari ADSs post-closing, adjusted for net cash.
- Voting agreements with ~39.5% of Akari shareholders and ~39.3% of Peak Bio stockholders to vote in favor.
- Conditions include $10M PIPE investment, S-4 effectiveness, Nasdaq listing, and no material adverse effect.
- Termination fee of $300,000 plus expense reimbursement up to $1.5 million under specified circumstances.

## SEC filing metadata
- accession: 0001104659-24-030777
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000110465924030777/0001104659-24-030777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000110465924030777/tm247836d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-030777
- JSON: https://secwatch.observer/filing/0001104659-24-030777.json
- Plain text: https://secwatch.observer/filing/0001104659-24-030777.txt

## Key facts
- Material Agreements
  Akari Therapeutics Plc entered into Agreement and Plan of Merger with Peak Bio, Inc. (effective 2024-03-04).
  - Action: entry
  - Agreement: merger
  - Counterparty: Peak Bio, Inc.
  - Effective: 2024-03-04
  source text: On March 4, 2024, Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (" Akari "), entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Peak Bio, Inc. (" Peak Bio ") and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (" Merger Sub ")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000110465924030777/0001104659-24-030777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.